33 results on '"Traussnigg, Stefan"'
Search Results
2. Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
3. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
4. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome
5. Hepatic steatosis in Wilson disease – Role of copper and PNPLA3 mutations
6. Vitamin D3 Loading Is Superior to Conventional Supplementation After Weight Loss Surgery in Vitamin D-Deficient Morbidly Obese Patients: a Double-Blind Randomized Placebo-Controlled Trial
7. Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency
8. Ultra‐high‐field magnetic resonance spectroscopy in non‐alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non‐alcoholic steatohepatitis and advanced fibrosis
9. Application of localized 31P MRS saturation transfer at 7 T for measurement of ATP metabolism in the liver: reproducibility and initial clinical application in patients with non-alcoholic fatty liver disease
10. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease
11. High- and ultra-high-field 3.0-T 1H- and 7.0-T 31P-MR spectroscopy prior to liver biopsy in patients with NAFLD allows non-invasive differentiation between fatty liver and NASH by profiling of hepatocellular lipid content and 31P metabolites: 1465
12. Prevalence of anti‐Hepatitis E antibodies and impact on disease severity in non‐alcoholic fatty liver disease
13. Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
14. Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects
15. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
16. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
17. Tu1907 – Liver Fibrosis Stage At Baseline Predicts Outcome of Metabolic Surgery
18. THU-333-The HSD17B13:TA (rs72613567) splice variant protects against severity of non-alcoholic fatty liver disease but not fibrosis
19. Prevalence of anti‐Hepatitis E antibodies and impact on disease severity in non‐alcoholic fatty liver disease.
20. norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study
21. Vitamin D3 Loading Is Superior to Conventional Supplementation After Weight Loss Surgery in Vitamin D-Deficient Morbidly Obese Patients: a Double-Blind Randomized Placebo-Controlled Trial
22. 24 Prevalence of Liver Fibrosis, Non-Invasive Liver Fibrosis Markers and Metabolic Signatures Among Morbidly Obese Patients
23. 1053 Bloom of Fecal Megamonas After a 4 Week High Oral Fructose Challenge Disturbs Energy and Lipid Metabolism: Linking Diet to Microbiota, Bile Acid and Host Metabolism Alterations
24. Difficult case of Cronkhite-Canada syndrome with small intestinal bacterial overgrowth,Clostridium difficileinfection and polymyalgia rheumatica
25. Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease
26. The link between obesity and vitamin D in bariatric patients with omega-loop gastric bypass surgery - a vitamin D supplementation trial to compare the efficacy of postoperative cholecalciferol loading (LOAD): study protocol for a randomized controlled trial
27. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH
28. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders
29. Noninvasive Differentiation of Simple Steatosis and Steatohepatitis by Using Gadoxetic Acid–enhanced MR Imaging in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study
30. 309 Role of Intestinal Permeability for Metabolic Disturbances After Fructose Overconsumption.
31. Therapeutic Role of Bile Acids and Nuclear Receptor Agonists in Fibrosing Cholangiopathies
32. Difficult case of Cronkhite-Canada syndrome with small intestinal bacterial overgrowth, Clostridium difficile infection and polymyalgia rheumatica.
33. Application of localized ³¹P MRS saturation transfer at 7 T for measurement of ATP metabolism in the liver: reproducibility and initial clinical application in patients with non-alcoholic fatty liver disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.